Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
14.00
-0.03 (-0.21%)
At close: Jul 31, 2026, 4:00 PM EDT
13.73
-0.27 (-1.93%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Generate Biomedicines Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Generate Biomedicines stock has a consensus rating of "Strong Buy" and an average price target of $25.4. The average 1-year stock price forecast is 81.43% higher than the current stock price, while the lowest is $22 (+57.14%) and the highest is $30 (+114.29%).
Price Target: $25.4 (+81.43%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 25, 2026.
Analyst Ratings
The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|
| Strong Buy | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Reiterates $30 | Buy | Reiterates | $30 | +114.29% | Jun 25, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $22 | Buy | Maintains | $20 → $22 | +57.14% | May 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $24 | Buy | Reiterates | $24 | +71.43% | May 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +78.57% | May 8, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $26 | Buy | Maintains | $26 | +85.71% | Apr 10, 2026 |
Financial Forecast
Revenue This Year
25.89M
from 31.89M
Decreased by -18.81%
Revenue Next Year
23.67M
from 25.89M
Decreased by -8.60%
EPS This Year
-2.24
EPS Next Year
-2.07
from -2.24
EPS and Forward PE are based on non-GAAP adjusted numbers.